Last reviewed · How we verify
Transdermal Contraceptive System
At a glance
| Generic name | Transdermal Contraceptive System |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential (PHASE3)
- Exploring the Modulatory Role of Sex Hormones Along the Neuromechanical Axis in Females
- Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles (PHASE3)
- Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
- Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women (PHASE2)
- Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System (PHASE3)
- Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females (PHASE1)
- Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: